Skip to content

Transcutaneous Auricular Vagus Nerve Stimulation for Pediatric Epilepsy

Transcutaneous Auricular Vagus Nerve Stimulation as a Complementary Treatment for Pediatric Epilepsy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02004340
Enrollment
120
Registered
2013-12-09
Start date
2013-11-30
Completion date
2016-12-31
Last updated
2015-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

pediatric epilepsy, transcutaneous vagus nerve stimulation

Brief summary

The purpose of this study is to determine whether transcutaneous auricular vagus nerve stimulation as a complementary therapy is effective in the treatment of pediatric epilepsy.

Interventions

DEVICEear vagus nerve stimulator

Sponsors

Beijing Tiantan Hospital
CollaboratorOTHER
Beijing Children's Hospital
CollaboratorOTHER
China Academy of Chinese Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Diagnosed as epilepsy; * With age between 2-18 years old; * The number and dose of the medication was kept constant no less than eight weeks before intervention; * The patients or their guardians can count the frequency of the seizures and finish the study.

Exclusion criteria

* The patient is receiving the VNS therapy; * Accompanied with progressive central nervous system diseases; * Have severe heart, liver ,kidney or blood diseases; * Be pregnant or having the schedule of pregnancy in the study period.

Design outcomes

Primary

MeasureTime frame
frequency of epileptic seizuresChange from baseline at 8, 16, 24 weeks respectively in frequency of epileptic seizures

Secondary

MeasureTime frame
Number of participants with adverse events as a measure of safety and tolerabilityparticipants will be followed for the duration of TVNS intervention, an expected average of 8 weeks

Countries

China

Contacts

Primary ContactWei He, Dr.
hazel7811@hotmail.com86 10 64089403

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026